There are many different aspects to the treatment and management of primary melanoma, but clinicians differ on their perceptions of the ideal treatment approach.
Radiodermatitis affects approximately 95% of all patients who receive radiation therapy for cancer - many of who are women undergoing breast cancer treatment. A recent study has found that developing the condition has a significant and detrimental impact on breast cancer patients' overall quality-of-life.
Researchers recently examined a non-invasive test that, if additional studies can confirm, may directly affect future patient care for patients at risk for non-melanoma skin cancer.
Joel Cohen, M.D., shares his response to recent findings regarding the safety of chemical sunscreen and discusses why patients should consider using physical sunscreens.
A new technology based on laser-induced breakdown spectroscopy has demonstrated accuracy in both sensitivity and specificity for discriminating skin cancers from benign lesions, one expert says.
Combined imaging modalities may help guide choice of treatment and prevent biopsy, according to one expert.
Accurately diagnosing some melanocytic neoplasms is challenging because they may fall into a grey area histologically, one expert says. Recent progress in molecular genetics can help dermatopathologists more precisely classify tumors, leading to more appropriate treatment and management choices.
GEP testing could improve staging accuracy and help streamline disease management, but more research is needed to determine if a high-risk GEP classification is associated with improved response to newer systemic therapies.
Dermatologists should work to gain a better understanding of immunologic pathways as well as the mechanisms of new and evolving immunotherapies, as these are key for understanding many current and emerging melanoma treatments, one expert says.
Laser-assisted drug delivery used to fractionally ablate the target area prior to topical medical treatment can be useful in patients with widespread actinic damage, says this expert.